

YUHAN CORPORATION

Company Introduction

September 2023



YUHAN CORPORATION


Founder of Yuhan, Dr. Ilhan New

Korean activist & entrepreneur
Donated all his wealth to a public education foundation



Core Business Areas

YUHAN's Worldwide Locations



Headquarter



R&D Institute



Manufacturing Facility

4 on-site R&BD open innovation offices

R&D Strength

- Fully integrated R&D teams covering from discoveries to clinical developments, with a strong point in translational research
- Translational research strength includes swift development capability from early to clinical stage
- Engaging various collaboration models to maximize the value of assets (licensing, R&D-based JV, early research collaborations)



- Early stage Program
- Basic Science
- Platform Technology

Right target

- ✓ Strong link between target and disease
- ✓ Differentiated efficacy
- ✓ Available and predictive biomarkers

Right tissue

- ✓ Adequate bioavailability and tissue exposure
- ✓ Definition of PD biomarkers
- ✓ Clear understanding of preclinical and clinical PK/PD

- Global Clinical Trial
- Approval/Marketing

Open Innovation: Values we seek

Oncology



- Targeted anticancer agents: Assets enabling biomarker-driven patients selection with feasible PD marker
- Immuno-oncology: Mechanism involved in innate or adaptive immune response

Metabolism/Fibrosis



- Novel mechanisms of action targeting metabolic disease or tissue fibrosis process (pulmonary, hepatic, renal fibrosis) with strong disease link

CNS



- Disease modifying therapeutic agents against neurodegenerative diseases (AD, PD, ALS, etc..)
- Novel targets other than pathologic aggregates with strong disease link

Emerging technology



- Targeted protein degradation: Harnessing new E3 ligases, novel E3 ligase binder, novel target protein of interest (POI), alternative TPD modalities (LYTAC, AUTAC, etc..)
- Drug RNA delivery technology: Novel lipid nanoparticles or polymer nanoparticles, Tissue targeting to CNS (including BBB shuttle for biologics), immune system, or tumor
- Therapeutic mRNA platform with improved mRNA stability and/or translational efficacy (e.g. circular RNA)



Thank you